Yazar "Kuku I." seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Bone relapse in a patient with acute lymphoblastic leukaemia(2005) Aydogdu I.; Erkurt A.M.; Kaya E.; Kuku I.[No abstract available]Öğe Evaluation of ferric and ferrous iron therapies in women with iron deficiency anaemia(Hindawi Publishing Corporation, 2014) Berber I.; Diri H.; Erkurt M.A.; Aydogdu I.; Kaya E.; Kuku I.Introduction. Different ferric and ferrous iron preparations can be used as oral iron supplements. Our aim was to compare the effects of oral ferric and ferrous iron therapies in women with iron deficiency anaemia. Methods. The present study included 104 women diagnosed with iron deficiency anaemia after evaluation. In the evaluations performed to detect the aetiology underlying the iron deficiency anaemia, it was found and treated. After the detection of the iron deficiency anaemia aetiology and treatment of the underlying aetiology, the ferric group consisted of 30 patients treated with oral ferric protein succinylate tablets (2 × 40 mg elemental iron/day), and the second group consisted of 34 patients treated with oral ferrous glycine sulphate tablets (2 × 40 mg elemental iron/day) for three months. In all patients, the following laboratory evaluations were performed before beginning treatment and after treatment. Results. The mean haemoglobin and haematocrit increases were 0.95 g/dL and 2.62% in the ferric group, while they were 2.25 g/dL and 5.91% in the ferrous group, respectively. A significant difference was found between the groups regarding the increase in haemoglobin and haematocrit values (P < 0.05). Conclusion. Data are submitted on the good tolerability, higher efficacy, and lower cost of the ferrous preparation used in our study. © 2014 Ilhami Berber et al.Öğe A multicentric, hyaline vascular variant of Castleman's disease associated with B cell lymphoma: A case report(2009) Erkurt M.A.; Aydogdu I.; Kuku I.; Kaya E.; Mizrak B.; Basaran Y.Introduction: Three histological variants (hyaline vascular, plasma cell, and mixed) and two clinical types (localized and multicentric) of Castleman's disease have been described. The risk of progression to lymphoma is higher in multicentric Castleman's disease and is associated with poorer outcomes and higher mortality rate. Multicentric Castleman's disease often requires systemic therapy. Complete resection of the involved node in localized Castleman's disease is curative, with no reported recurrences. Case presentation: We report a case of a 66-year-old female with systemic symptoms and bilateral cervical lymph nodes which were initially diagnosed as the hyaline vascular variant of Castleman's disease and two years later after the initial diagnosis she was confirmed to B cell lymphoma. Following the treatment with radiation therapy to the cervical area and combination chemotherapy complete response was achieved. Conclusion: Although it has rarely been reported, the malignant potential of the Castleman's disease must be kept in mind. © 2009 Erkurt et al; licensee Cases Network Ltd.Öğe Nodular melanoma presenting with rapid progression and widespread metastases: A case report(2009) Erkurt M.A.; Aydogdu I.; Kuku I.; Kaya E.; Basaran Y.Introduction: Melanoma is responsible for 1% to 2% of all cancer deaths around the world. Nodular melanoma often carries a poor prognosis because of no prodromal radial growth phase, early distant metastasis and significant tumor volume. Case presentation: We present a case of progressive melanoma. A 51-year-old man was admitted to our hospital with dyspnea and skin lesions. These were multiple, dark colored, firm, and nodular and varied in size. He was diagnosed with melanoma. Temozolomide was administered, but he died of respiratory failure within a week after diagnosis. Conclusion: Nodular melanoma tends to spread rapidly and eventually metastasize to vital organs. It may be fatal within months of recognition. © 2009 Erkurt et al; licensee BioMed Central Ltd.Öğe Rapid progression of acquired amegakaryocytic thrombocytopenia to myelodysplastic syndrome: Case report(2005) Erkurt M.A.; Kaya E.; Baran M.; Yitmen E.; Şenel S.; Kuku I.; Aydo?du I.Acquired amegakaryocytic thrombocytopenia (AAT) is a rare disease characterized by severe thrombocytopenia due to selective reduction or absence of megakaryocytes in the bone marrow. More commonly, patients with AAT have additional hematologic abnormalities such as macrocytosis or dyserythropoiesis, abnormalities which may predict progression to aplastic anemia or myelodysplasia. A 52-year-old female was admitted to hospital with mucosal and gingival bleeding. Megakaryocytes were not seen on the bone marrow aspiration and biopsy. AAT was diagnosed. Although she was treated with immunosuppressive therapy including prednisolone and cyclosporine, her disease progressed to myelodysplastic syndrome. She died at the third month of diagnosis because of cerebral bleeding.Öğe A rare syndrome that can easily be missed: May-Hegglin anomaly(2005) Aydo?du I.; Kaya E.; Kuku I.; Ali Erkurt M.; Görgel A.; Özhan O.May-Hegglin is a rare disease characterized by macrothrombocytopenia and presence of Döhle-like bodies in white cells. We present a patient treated with acute myeloid leukemia had pale-blue colored inclusion bodies assuming Döhle in his neutrophils.
